Link to the full report here
1. Executive Summary
MARA Rating has completed a formal surveillance review of CagriSema (cagrilintide + semaglutide) following publication of Phase 3 head-to-head results versus tirzepatide.
As of July 2025, CagriSema held an A (Strong) MARA Rating, indicating a good probability of achieving broad reimbursement with manageable risk.
Based on new comparative evidence, the rating has been revised to:
B++ (Marginal)
This action reflects a change in reimbursement probability under HTA evaluation standards — not a statement on regulatory approval.
2. What Triggered the Surveillance Review?
Under MARA’s published methodology, ratings are placed under review when material evidence emerges that could affect one or more of the ten evaluation domains.
The trigger in this case:
- Phase 3 head-to-head trial results versus tirzepatide
- Failure to meet the predefined non-inferiority objective
- Increased uncertainty in comparative positioning within the obesity therapeutic class
Comparative performance against active standard-of-care comparators is a central determinant of HTA outcomes in major markets.
3. Domains Impacted
The downgrade was driven by adjustments in three domains:
Clinical Effectiveness
While placebo-controlled efficacy remains strong, relative performance versus tirzepatide introduces competitive uncertainty under HTA frameworks that prioritize incremental benefit.
Health-Related Quality of Life (HRQoL)
Absence of broader utility data (e.g., EQ-5D) limits quantifiable differentiation in cost-utility modeling.
Uncertainty, Sensitivity & Broader Impacts
Failure to demonstrate non-inferiority increases scenario sensitivity in economic modeling and payer negotiations.
Other domains — including Safety and Evidence Quality — remain structurally strong.
4. What the Downgrade Means
Under MARA’s rating scale:
- A (Strong) → Good probability of broad reimbursement; manageable risks
- B++ (Marginal) → Reimbursement possible, but finely balanced; elevated risk of price pressure, restrictions, or negotiation intensity
The shift does not imply rejection.
It signals a narrower margin under HTA scrutiny, particularly in competitive markets where incremental benefit versus tirzepatide will be central to assessment.
5. Why This Matters
Clinical success does not equal commercial access.
HTA bodies evaluate:
- Incremental benefit versus active comparators
- Cost-effectiveness relative to established alternatives
- Budget impact in the context of class competition
When comparative evidence weakens, reimbursement probability changes — even if absolute efficacy remains high.
Without a standardized benchmark, such shifts are often absorbed subjectively within internal forecasts.
MARA enforces comparability across time and assets by applying the same structured framework before and after new evidence.
6. Methodological Integrity
This action reflects MARA’s surveillance policy:
- Continuous monitoring of material evidence
- Structured domain-level reassessment
- Human-in-the-loop expert validation
- Evidence-linked rationale
Ratings are dynamic by design.
Credibility depends on adjustment when data changes.
7. Implication for Decision-Makers
For:
- Portfolio strategy teams
- M&A diligence committees
- Investors assessing obesity assets
- Market Access planning functions
The relevant question is:
If this decision is challenged later, what independent benchmark did you rely on?
MARA provides that benchmark.
Follow MARA Rating for formal surveillance updates.
Access the full CagriSema rating report in our catalogue.